Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METHYLIN ER vs ADDERALL 30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their availability in the synaptic cleft.
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
20-60 mg orally once daily in the morning
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
Mean 3-6 hours in adults; longer in children (4-8 hours). Clinical context: steady-state reached within 2 days; dosing every 8-12 hours.
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Primarily de-esterified by carboxylesterase 1 (CES1) to the inactive metabolite ritalinic acid. Minor hepatic metabolism via CYP2D6.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2B6, and CYP3A4.
Renal (90% as metabolites, <1% unchanged). Biliary/fecal: <2%.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
Methylphenidate: 10-33%, primarily to albumin. Metabolite ritalinic acid: ~50% bound.
Approximately 20-25% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
2.6-4.0 L/kg. Indicates extensive tissue distribution.
Vd: 3-4 L/kg (approximately 210-280 L for a 70 kg adult). This indicates extensive tissue distribution and penetration into the central nervous system.
Oral: 11-52% (low and variable due to first-pass metabolism).
Oral immediate-release: approximately 75-100%; oral extended-release: approximately 94% relative to immediate-release. Food does not significantly affect absorption but may delay peak concentration.
No adjustment needed for GFR >30 m L/min; insufficient data for GFR <30 m L/min
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use
Child-Pugh Class A: no adjustment; Class B or C: reduce dose by 50%
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
6 years and older: 18-54 mg orally once daily; weight-based: 0.3-1 mg/kg/dose, max 54 mg/day; not recommended under 6 years
Children 3-5 years: initial 2.5 mg orally once daily; increase by 2.5 mg weekly; usual range 2.5-20 mg/day. Children ≥6 years: initial 5 mg once or twice daily; increase by 5 mg weekly; usual range 5-40 mg/day in divided doses
Start at low end of dosing range (20 mg daily) due to potential increased sensitivity; monitor cardiovascular status
Initiate at 2.5 mg orally once or twice daily; titrate slowly; monitor for cardiovascular effects, insomnia, and weight loss
Abuse and dependence: CNS stimulants, including methylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Risk of abuse and dependence,Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Blood pressure and heart rate increase,Psychiatric adverse events: exacerbation of pre-existing psychosis, mania, aggression, new psychotic or manic symptoms,Seizures: may lower seizure threshold,Priapism,Peripheral vasculopathy including Raynaud's phenomenon,Long-term suppression of growth in pediatric patients
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Serotonin syndrome risk when co-administered with serotonergic drugs,Long-term suppression of growth in children,Seizure risk in patients with history of seizures,Peripheral vasculopathy including Raynaud's phenomenon,Visual disturbances due to mydriasis
Hypersensitivity to methylphenidate or any component of the formulation,Concurrent treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing an MAOI,Glaucoma,Tics or family history of Tourette's syndrome,Severe hypertension or symptomatic cardiovascular disease,Hyperthyroidism
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity to amphetamines,Agitated states,History of drug abuse,During or within 14 days of MAO inhibitor use,Glaucoma
Avoid alcohol, which may increase risk of cardiovascular side effects. Food does not significantly affect absorption of extended-release formulation, but acidic foods/beverages may reduce absorption if taken simultaneously.
Avoid high-fat meals as they delay absorption; avoid acidic foods (e.g., citrus) and vitamin C supplements within 1 hour of dosing as they decrease absorption; limit caffeine and other stimulants to avoid additive cardiovascular effects.
Methylphenidate is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of fetal anomalies (cardiac, skeletal) at high doses. Second trimester: Potential for decreased fetal growth with chronic use. Third trimester: Risk of neonatal withdrawal syndrome (tachycardia, irritability, poor feeding) and premature delivery.
Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, lassitude). Chronic use may lead to neonatal toxicity.
Methylphenidate is excreted into human breast milk with an M/P ratio of approximately 2-3 (range 1.1-4.4). Infant exposure is estimated at 0.2-0.7% of maternal weight-adjusted dose. Use with caution; monitor infant for agitation, insomnia, and reduced weight gain.
Excreted in breast milk. M/P ratio unknown. Potential for stimulant effects in infant (e.g., irritability, poor feeding, insomnia). Caution advised; consider alternative feeding methods.
Methylphenidate clearance may increase in pregnancy due to enhanced hepatic metabolism (CYP2D6 and CES1). Dose adjustments are often required; titrate to lowest effective dose based on clinical response. Plasma levels may drop by 30-50% in the third trimester, necessitating increased dose or extended-release formulations. Postpartum dose reduction may be needed.
No established dosing guidelines. Due to increased plasma volume and clearance, dose may need titration to clinical effect, but avoid supratherapeutic doses. Use lowest effective dose.
Do not crush or chew extended-release tablets; capsule can be opened and sprinkled on applesauce. Monitor for weight loss and growth suppression in pediatric patients. Avoid use within 14 days of MAOIs. Use with caution in patients with hypertension, hyperthyroidism, glaucoma, or history of substance abuse. May lower seizure threshold.
For ADHD: start low, go slow; monitor weight and height in children; avoid late doses to prevent insomnia; check for abuse/diversion; screen for bipolar disorder and hypertension; consider urine drug screen before prescribing; avoid MAOIs within 14 days; use with caution in seizure disorders and glaucoma.
Take exactly as prescribed; do not alter dose or frequency without consulting doctor.,Swallow tablets whole; do not crush, chew, or break.,Avoid alcohol while taking this medication.,Report any chest pain, shortness of breath, or fainting.,Regular monitoring of blood pressure and heart rate is needed.,May cause difficulty sleeping; take last dose of short-acting forms early in the day.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not crush or chew capsules.,Take the first dose upon waking; avoid afternoon/evening doses.,May cause insomnia, loss of appetite, or nervousness.,Do not drink alcohol while taking this medication.,Report chest pain, palpitations, shortness of breath, or mood changes.,Store securely; do not share medication with others.,Regular blood pressure and heart rate monitoring is necessary.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METHYLIN ER vs ADDERALL 30, answered by our medical review team.
METHYLIN ER is a CNS Stimulant that works by Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their availability in the synaptic cleft.. ADDERALL 30 is a CNS Stimulant that works by Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METHYLIN ER and ADDERALL 30 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METHYLIN ER is: 20-60 mg orally once daily in the morning. The standard adult dose of ADDERALL 30 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METHYLIN ER and ADDERALL 30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METHYLIN ER is classified as Category C. Methylphenidate is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of fetal anomalies (cardiac, skeletal) at high do. ADDERALL 30 is classified as Category C. Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.